JavaScript is disabled in your browser. Please enable JavaScript to view this website.

APOA5

Function

Minor apolipoprotein mainly associated with HDL and to a lesser extent with VLDL. May also be associated with chylomicrons. Important determinant of plasma triglyceride (TG) levels by both being a potent stimulator of apo-CII lipoprotein lipase (LPL) TG hydrolysis and an inhibitor of the hepatic VLDL-TG production rate (without affecting the VLDL-apoB production rate) (By similarity). Activates poorly lecithin:cholesterol acyltransferase (LCAT) and does not enhance efflux of cholesterol from macrophages. Binds heparin (PubMed:17326667).

Involvement in disease

Hypertriglyceridemia 1

HYTG1

A common inherited disorder in which the concentration of very low density lipoprotein (VLDL) is elevated in the plasma. This leads to increased risk of heart disease, obesity, and pancreatitis. Inheritance is autosomal dominant.

None

Disease susceptibility is associated with variants affecting the gene represented in this entry.

Hyperlipoproteinemia 5

HLPP5

Characterized by increased amounts of chylomicrons and very low density lipoprotein (VLDL) and decreased low density lipoprotein (LDL) and high density lipoprotein (HDL) in the plasma after a fast. Numerous conditions cause this phenotype, including insulin-dependent diabetes mellitus, contraceptive steroids, alcohol abuse, and glycogen storage disease type 1A (GSD1A).

None

The disease is caused by variants affecting the gene represented in this entry.

Post-translational modifications

Phosphorylated by FAM20C in the extracellular medium.

Sequence Similarities

Belongs to the apolipoprotein A1/A4/E family.

Tissue Specificity

Liver and plasma.

Cellular localization

Alternative names

RAP3, UNQ411/PRO773, APOA5, Apolipoprotein A-V, Apo-AV, ApoA-V, Apolipoprotein A5, Regeneration-associated protein 3

swissprot:Q6Q788 entrezGene:116519 omim:606368